Navigation Links
Onyx Pharmaceuticals Reports 2008 First Quarter Results
Date:5/6/2008

Nexavar Net Sales increase 149% over First Quarter 2007

EMERYVILLE, Calif., May 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the first quarter ended March 31, 2008. Onyx reported net income of $15.4 million, or $0.27 per diluted share, for the first quarter of 2008 compared to a net loss of $12.2 million, or $0.26 per diluted share, in the same period in 2007.

Nexavar net sales as reported by Bayer HealthCare Pharmaceuticals, Inc., or Bayer, were $151.9 million for the first quarter ended March 31, 2008, a 149% increase over the $60.9 million reported in the same period in 2007. Onyx with its collaborator, Bayer, is marketing and developing Nexavar(R) (sorafenib) tablets, an anticancer therapy currently approved for the treatment of liver cancer and advanced kidney cancer in the United States, European Union, and other territories internationally.

"We are pleased with Nexavar's strong performance in the first quarter of 2008, generating worldwide net sales of $151.9 million, which we attribute to the continued successful launch of Nexavar in liver cancer in both the United States and in the rest of the world," said Tony Coles, M.D., president and chief executive officer of Onyx. "While we continue the global launch of Nexavar in liver cancer, we are focusing commercial efforts on the further development of this new market to support the long-term growth of this important opportunity. At the same time, we are investing in a broad clinical program to realize the potential benefits of Nexavar in numerous other tumor types."

The net profit for the first quarter ended March 31, 2008, included employee stock-based compensation expense of $5.2 mil
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  Indivior PLC (LON: INDV) today announced ... spray was accepted and received Priority Review by the ... of opioid overdose. This naloxone nasal spray comes as ... optimal absorption into the nasal mucosa. 1 The ... individuals may be better equipped to help an opioid ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi LifeSciences™ ... Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized in strategic, ... expertise of PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, ...
(Date:7/29/2015)... Littleton, MA (PRWEB) , ... July 29, 2015 , ... ... range of serious diseases. Yet few people realize that a rich source of these ... or young adults, and teeth that need to be pulled to make room for ...
(Date:7/28/2015)... 28, 2015 People with a common form ... significant and sometimes profound improvements in their hearing and ... to a new multicenter study led by specialists at ... described online ahead of print in the journal The Laryngoscope ... clinics in the United States ...
Breaking Biology Technology:Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Tooth™ Dental Stem Cell Banking Available to their Patients 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3
... Diego, ... October 4 ... - 7, 2007 -, CHICAGO, Oct. 2 Advanced Life Sciences,Holdings, Inc. ... drugs in the,therapeutic areas of infection, cancer and inflammation, will present four,posters at the Infectious ...
... Pa., Oct. 2 Monitorforhire.com, the,fastest source ... its,service even faster. The company has added ... and respond immediately to work requests via,PDA ... Scott Freedman, president of monitorforhire.com says ...
... Global Advocacy Groups Launch Joint Effort to Preserve Eyesight of,Millions ... reveal that eye exams are being,ignored by many aged over ... in the last year to have their eyes checked, even ... disease or early,death. The survey showed that awareness of glaucoma ...
Cached Biology Technology:Advanced Life Sciences to Present Data from Selected Cethromycin Clinical Trials at the 45th Annual Meeting of the Infectious Diseases Society of America 2Advanced Life Sciences to Present Data from Selected Cethromycin Clinical Trials at the 45th Annual Meeting of the Infectious Diseases Society of America 3International Survey Shows People Over Forty Ignore Risk of Blindness 2International Survey Shows People Over Forty Ignore Risk of Blindness 3International Survey Shows People Over Forty Ignore Risk of Blindness 4International Survey Shows People Over Forty Ignore Risk of Blindness 5
(Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
(Date:7/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), a leading developer ... report financial results for the fourth quarter and fiscal ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-455-2260 (conference ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... have developed a number of ways to communicate those times ... One means of this communication occurs through scent marking. ... with researchers at the Institute of Zoology, Chinese Academy of ... what trees are used for scent marking. , "Variables ...
... created equal. Some types of fats have been linked to ailments ... in plants and fish, have well documented health benefits. ... but not others? A new hypothesis described in latest ... answer may lie in how different fats interact with the microbes ...
... Ohio - Some RNA molecules spend time in a restful ... established job of delivering protein-building instructions in cells, new research ... mistake, the research suggests that this restful period appears to ... of genes, including some that control cell division and decide ...
Cached Biology News:The Quarterly Review of Biology: Why some fats are worse than others 2To cap or not to cap: Scientists find new RNA phenomenon that challenges dogma 2To cap or not to cap: Scientists find new RNA phenomenon that challenges dogma 3To cap or not to cap: Scientists find new RNA phenomenon that challenges dogma 4
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
...
...
... PI is used in conjuction with Annexin ... the earlier stages of apoptosis (Annexin V ... in later stages of apoptosis or already ... is detected in the orange range of ...
Biology Products: